{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Arichall_400x400.jpg|frameless|upright=0.3|center]]
|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1]
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
<big>'''Note: most of these regimens include complex dose adjustments based on therapeutic troughs, concomitant medications, and other factors. Therefore, the focus on this page will be inclusion of drug names and references, but not necessarily drug dosages.'''</big>
{{TOC limit|limit=3}}
=Guidelines=
=="How we treat"==
*'''2014:''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease]

=Prevention=
''This is very basic for now, to expand in the future. Information can also be found under individual regimens on the [[Allogeneic_HSCT|allogeneic HSCT]] page.''
==Cyclosporine & Methotrexate==
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70225-6/fulltext Finke et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cyclosporine.2C_Methotrexate.2C_ATG|Cyclosporine, MTX, ATG]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#eeee01" |Similar NRM
|-
|}
''Note: while the study did not meet its primary endpoint, there was a clear finding of superior control of cGVHD in the experimental arm.''
====GVHD prophylaxis====
*[[:Category:Cyclosporines|Cyclosporine]]
*[[Methotrexate (MTX)]]
===References===
# Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70225-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19695955 PubMed]
## '''Update:''' Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011 Jun 9;117(23):6375-82. Epub 2011 Apr 5. [http://www.bloodjournal.org/content/117/23/6375.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21467544 PubMed]

==Cyclosporine, Methotrexate, ATG==
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70225-6/fulltext Finke et al. 2009]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cyclosporine_.26_Methotrexate|Cyclosporine & MTX]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#eeee01" |Similar NRM
|-
|}
''Note: while the study did not meet its primary endpoint, there was a clear finding of superior control of cGVHD in the experimental arm.''
====GVHD prophylaxis====
*[[:Category:Cyclosporines|Cyclosporine]]
*[[Methotrexate (MTX)]]
*[[Antithymocyte globulin, rabbit ATG (Grafalon)|Antithymocyte globulin, rabbit ATG (ATG-Fresenius)]]
===References===
# Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. Epub 2009 Aug 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70225-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19695955 PubMed]
## '''Update:''' Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011 Jun 9;117(23):6375-82. Epub 2011 Apr 5. [http://www.bloodjournal.org/content/117/23/6375.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21467544 PubMed]

==Cyclosporine, Methotrexate, MP==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9126b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/96/7/2391.long Ruutu et al. 2000]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cyclosporine_.26_Methotrexate|Cyclosporine & MTX]]
| style="background-color:#1a9850" |Lower rate of aGVHD
|-
|}
====Immunosuppressive therapy====
*[[Cyclosporine modified (Neoral)]]
*[[Methotrexate (MTX)]]
*[[Methylprednisolone (Solumedrol)]]
===References===
# Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood. 2000 Oct 1;96(7):2391-8. [http://www.bloodjournal.org/content/96/7/2391.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11001889 PubMed]
## '''Update:''' Ruutu T, Nihtinen A, Niittyvuopio R, Juvonen E, Volin L. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis. Cancer. 2018 Feb 15;124(4):727-733. Epub 2017 Nov 7. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.31100/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29112242 PubMed]

==Cyclosporine, Methotrexate, Prednisone==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:81a6b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199310213291703 Chao et al. 1993]
| style="background-color:#1a9851" |Phase III (E)
|Cyclosporine & Prednisone
| style="background-color:#91cf60" |Seems to have lower rate of grade II to IV aGVHD
|-
|}
====Immunosuppressive therapy====
*[[Cyclosporine modified (Neoral)]]
*[[Methotrexate (MTX)]]
*[[Prednisone (Sterapred)]]
===References===
# Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993 Oct 21;329(17):1225-30. [https://www.nejm.org/doi/full/10.1056/NEJM199310213291703 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8413388 PubMed]

==Methotrexate, Tacrolimus, Tocilizumab {{#subobject:fe1c2e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2d492b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865423/ Drobyski et al. 2018]
|style="background-color:#91cf61"|Phase II
|-
|}
====Immunosuppressive therapy====
*[[Methotrexate (MTX)]]
*[[Tacrolimus (Prograf)]]
*[[Tocilizumab (Actemra)]]
===References===
# Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. Epub 2018 Jan 19. [http://www.haematologica.org/content/103/4/717 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865423/ linkt o PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29351985 PubMed]

==Methotrexate, Tacrolimus, Vorinostat {{#subobject:ca16a7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:191ac5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/130/15/1760.long Choi et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Immunosuppressive therapy====
*[[Methotrexate (MTX)]] 5 mg/m<sup>2</sup> IV once per day on days +1, +3, +6, +11
*[[Tacrolimus (Prograf)]] by one of the following routes, starting on day -3:
**IV: 0.03 mg/kg/day
**PO: 0.045 mg/kg/day
**Goal trough level of 8 to 12 ng/mL
**In absence of GVHD, tapering begins on day +100 and completes on day +180
*[[Vorinostat (Zolinza)]] 100 mg PO twice per day on days -10 to +100

===References===
# Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, Pawarode A, Riwes M, Yanik G, Dinarello CA, Reddy P. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 Oct 12;130(15):1760-1767. Epub 2017 Aug 7. [http://www.bloodjournal.org/content/130/15/1760.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28784598 PubMed]

==Rabbit ATG==
====Immunosuppressive therapy====
*[[Antithymocyte globulin, rabbit ATG (Thymoglobulin)]]

===References===
# Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R; Canadian Blood and Marrow Transplant Group. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016 Feb;17(2):164-173. Epub 2015 Dec 24. [https://www.ncbi.nlm.nih.gov/pubmed/26723083 PubMed]
# Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016 Jan 7;374(1):43-53. [https://www.nejm.org/doi/full/10.1056/NEJMoa1506002 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26735993 PubMed]
# Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, Merli P, Pagliara D, Prete A, Zecca M. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1126-1136. Epub 2017 Jul 10. [https://www.ncbi.nlm.nih.gov/pubmed/28705454 PubMed]

=Treatment, aGVHD, all lines of therapy=

=Treatment, cGVHD, all lines of therapy=
==Cyclosporine & Prednisone {{#subobject:7a7c79|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c940ce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bbmt.org/article/S1083-8791(01)50043-9/fulltext Arora et al. 2001]
|style="background-color:#1a9851"|Randomized (C)
|Cyclosporine, Prednisone, Thalidomide
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunosuppressive therapy====
*[[:Category:Cyclosporines|Cyclosporine]]
*[[Prednisone (Sterapred)]]
===References===
# Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, Miller WJ, Weisdorf DF. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(5):265-73. [http://www.bbmt.org/article/S1083-8791(01)50043-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11400948 PubMed]

==Cyclosporine, Corticosteroids, Rituximab {{#subobject:9fffb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:0de254|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/130/20/2186.long Malard et al. 2017]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d4d4d4"|ORR at 12 mo: 83%
|-
|}
====Immunosuppressive therapy====
*[[:Category:Cyclosporines|Cyclosporine]] 6 mg/kg PO twice per day
**Or, continued at the dose at time of study entry
**Goal level 200 to 400 ng/mL
*[[:Category:Steroids|Corticosteroids]] equivalent to 1 mg/kg/day of [[Prednisone (Sterapred)]]
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

''Rituximab given as a 4-week course, repeated one month later if PR or better. Corticosteroids and CsA tapered per standard of care.''

===References===
# Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, Tabrizi R, Magro L, Vanhove B, Blancho G, Moreau P, Gaugler B, Chevallier P, Mohty M. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017 Nov 16;130(20):2186-2195. Epub 2017 Sep 1. [http://www.bloodjournal.org/content/130/20/2186.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28864814 PubMed]

==Cyclosporine, Sirolimus, Prednisone {{#subobject:1ffc79|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cc1bce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/103/11/1915 Carpenter et al. 2018 (BMT CTN 0801)]
|style="background-color:#1a9851"|Phase II/III (C)
|Sirolimus & Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunosuppressive therapy====
*[[:Category:Cyclosporines|Cyclosporine]]
*[[Sirolimus (Rapamune)]]
*[[Prednisone (Sterapred)]]
===References===
# '''BMT CTN 0801:''' Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN. A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica. 2018 Nov;103(11):1915-1924. Epub 2018 Jun 28. [http://www.haematologica.org/content/103/11/1915 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29954931 PubMed]

==Ibrutinib monotherapy {{#subobject:5d9394|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7f34b4|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/130/21/2243.long Miklos et al. 2017]
|style="background-color:#91cf61"|Phase 1b/2
| style="background-color:#bfd3e6" |Best ORR: 67%
|-
|}
====Immunosuppressive therapy====
*[[Ibrutinib (Imbruvica)]] 420 mg PO once per day

===References===
# Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 Nov 23;130(21):2243-2250. Epub 2017 Sep 18. [http://www.bloodjournal.org/content/130/21/2243.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28924018 PubMed]

==Sirolimus, Tacrolimus, Prednisone {{#subobject:05e07b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bc128c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/103/11/1915 Carpenter et al. 2018 (BMT CTN 0801)]
|style="background-color:#1a9851"|Phase II/III (C)
|Sirolimus & Prednisone
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Immunosuppressive therapy====
*[[Sirolimus (Rapamune)]]
*[[Tacrolimus (Prograf)]]
*[[Prednisone (Sterapred)]]
===References===
# '''BMT CTN 0801:''' Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M; BMT CTN. A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica. 2018 Nov;103(11):1915-1924. Epub 2018 Jun 28. [http://www.haematologica.org/content/103/11/1915 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29954931 PubMed]

=Response criteria=
==2005 NIH cGVHD Consensus Panel==
===References===
# Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66. [http://www.bbmt.org/article/S1083-8791(06)00070-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16503494 PubMed]

==2014 NIH Response Criteria==
===References===
# Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. Epub 2015 Mar 19. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744804/ link to PMC article]

=Scoring=
==Glucksberg acute graft versus host (GVHD) scores== 
===Skin===
*Stage 0: No rash
*Stage 1: Maculopapular rash <25% of body surface area
*Stage 2: Maculopapular rash on 25-50% of body surface area
*Stage 3: Generalized erythroderma
*Stage 4: Generalized erythroderma with bullous formation and desquamation

===Liver===
*Stage 0: Bilirubin <2 mg/dL
*Stage 1: Bilirubin 2-3 mg/dL
*Stage 2: Bilirubin 3.01-6 mg/dL
*Stage 3: Bilirubin 6.01-15.0 mg/dL
*Stage 4: Bilirubin >15 mg/dL

===GI===
*Stage 0: No diarrhea, or diarrhea <500 mL/day
*Stage 1: Diarrhea 500-999 mL/day
*Stage 2: Diarrhea 1000-1499 mL/day
*Stage 3: Diarrhea >1500 mL/day
*Stage 4: Severe abdominal pain, with or without ileus

===Glucksberg grade===
{| class="wikitable" style="text-align:center;"
!align="left" | Overall grade
!I
!II
!III
!IV
|-
|align="left" | Skin
|1-2
|1-3
|2-3
|2-4
|-
|align="left" | GI
|0
|1
|2-3
|2-4
|-
|align="left" | Liver
|0
|1
|2-4
|2-4
|-
|Karnofsky performance scale
|90-100%
|70-80%
|50-60%
|30-40%
|-
|}

===IBMTR severity index===

The severity is the highest level which the patient reaches based on separate skin, liver, and GI staging.

{| class="wikitable" style="text-align:center;"
!align="left" | Overall grade
!A
!B
!C
!D
|-
|align="left" | Skin
|1
|2
|3
|4
|-
|align="left" | GI
|0
|1-2
|3
|4
|-
|align="left" | Liver
|0
|1-2
|3
|4
|-
|}

==Chronic GVHD==
===Localized===
*Localized skin and/or liver dysfunction due to chronic GVHD

===Extensive===
*Generalized skin involvement or localized skin and/or liver dysfunction due to chronic GVHD '''plus at least one of the following''':
**Liver biopsy showing cirrhosis, chronic aggressive hepatitis, bridging necrosis
**Eye involvement, defined as [http://en.wikipedia.org/wiki/Schirmer's_test Schirmer's test] with <5 mm wetting
**Involvement of oral mucosa on lip biopsy or minor salivary glands
**Other organ involvement
*Overall severity categories: mild/moderate/severe

==References==
# Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975 Apr 17;292(16):832-43 [https://www.nejm.org/doi/full/10.1056/NEJM197504172921605 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/234595 PubMed]
# Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975 Apr 24;292(17):895-902 [https://www.nejm.org/doi/full/10.1056/NEJM197504242921706 link to original article] '''(contains staging scale)''' [https://www.ncbi.nlm.nih.gov/pubmed/235092 PubMed]
# Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997 Jun;97(4):855-64. [https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.1112925.x/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9217189 PubMed]

[[Category:Graft versus host disease (GVHD) regimens]]
[[Category:Disease-specific pages]]
[[Category:Alloimmune hematologic conditions]]
